These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

448 related items for PubMed ID: 19171713

  • 1. Overall genomic pattern is a predictor of outcome in neuroblastoma.
    Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, Vermeulen J, Couturier J, Peuchmaur M, Valent A, Plantaz D, Rubie H, Valteau-Couanet D, Thomas C, Combaret V, Rousseau R, Eggert A, Michon J, Speleman F, Delattre O.
    J Clin Oncol; 2009 Mar 01; 27(7):1026-33. PubMed ID: 19171713
    [Abstract] [Full Text] [Related]

  • 2. Accumulation of segmental alterations determines progression in neuroblastoma.
    Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J, Pierron G, Mosseri V, Valent A, Auger N, Plantaz D, Rubie H, Valteau-Couanet D, Bourdeaut F, Combaret V, Bergeron C, Michon J, Delattre O.
    J Clin Oncol; 2010 Jul 01; 28(19):3122-30. PubMed ID: 20516441
    [Abstract] [Full Text] [Related]

  • 3. Bladder cancer stage and outcome by array-based comparative genomic hybridization.
    Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T, Pejavar S, Mehta K, Carroll P, Simko JP, Waldman FM.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 1):7012-22. PubMed ID: 16203795
    [Abstract] [Full Text] [Related]

  • 4. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.
    Brinkschmidt C, Christiansen H, Terpe HJ, Simon R, Lampert F, Boecker W, Dockhorn-Dworniczak B.
    Med Pediatr Oncol; 2001 Jan 01; 36(1):11-3. PubMed ID: 11464859
    [Abstract] [Full Text] [Related]

  • 5. Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization.
    Scaruffi P, Coco S, Cifuentes F, Albino D, Nair M, Defferrari R, Mazzocco K, Tonini GP.
    Cancer Genet Cytogenet; 2007 Aug 01; 177(1):20-9. PubMed ID: 17693187
    [Abstract] [Full Text] [Related]

  • 6. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression.
    Mosse YP, Diskin SJ, Wasserman N, Rinaldi K, Attiyeh EF, Cole K, Jagannathan J, Bhambhani K, Winter C, Maris JM.
    Genes Chromosomes Cancer; 2007 Oct 01; 46(10):936-49. PubMed ID: 17647283
    [Abstract] [Full Text] [Related]

  • 7. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
    Ladenstein R, Ambros IM, Pötschger U, Amann G, Urban C, Fink FM, Schmitt K, Jones R, Slociak M, Schilling F, Ritter J, Berthold F, Gadner H, Ambros PF.
    Med Pediatr Oncol; 2001 Jan 01; 36(1):83-92. PubMed ID: 11464912
    [Abstract] [Full Text] [Related]

  • 8. Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma.
    Spitz R, Hero B, Ernestus K, Berthold F.
    Clin Cancer Res; 2003 Oct 15; 9(13):4835-40. PubMed ID: 14581355
    [Abstract] [Full Text] [Related]

  • 9. Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome.
    Spitz R, Oberthuer A, Zapatka M, Brors B, Hero B, Ernestus K, Oestreich J, Fischer M, Simon T, Berthold F.
    Genes Chromosomes Cancer; 2006 Dec 15; 45(12):1130-42. PubMed ID: 16958102
    [Abstract] [Full Text] [Related]

  • 10. MYCN protein expression as a predictor of neuroblastoma prognosis.
    Chan HS, Gallie BL, DeBoer G, Haddad G, Ikegaki N, Dimitroulakos J, Yeger H, Ling V.
    Clin Cancer Res; 1997 Oct 15; 3(10):1699-706. PubMed ID: 9815553
    [Abstract] [Full Text] [Related]

  • 11. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.
    Caron H, van Sluis P, de Kraker J, Bökkerink J, Egeler M, Laureys G, Slater R, Westerveld A, Voûte PA, Versteeg R.
    N Engl J Med; 1996 Jan 25; 334(4):225-30. PubMed ID: 8531999
    [Abstract] [Full Text] [Related]

  • 12. ArrayCGH-based classification of neuroblastoma into genomic subgroups.
    Michels E, Vandesompele J, De Preter K, Hoebeeck J, Vermeulen J, Schramm A, Molenaar JJ, Menten B, Marques B, Stallings RL, Combaret V, Devalck C, De Paepe A, Versteeg R, Eggert A, Laureys G, Van Roy N, Speleman F.
    Genes Chromosomes Cancer; 2007 Dec 25; 46(12):1098-108. PubMed ID: 17823929
    [Abstract] [Full Text] [Related]

  • 13. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
    Krams M, Hero B, Berthold F, Parwaresch R, Harms D, Rudolph P.
    Cancer; 2002 Feb 01; 94(3):854-61. PubMed ID: 11857322
    [Abstract] [Full Text] [Related]

  • 14. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma.
    Bourhis J, De Vathaire F, Wilson GD, Hartmann O, Terrier-Lacombe MJ, Boccon-Gibod L, McNally NJ, Lemerle J, Riou G, Bénard J.
    Cancer Res; 1991 Jan 01; 51(1):33-6. PubMed ID: 1988094
    [Abstract] [Full Text] [Related]

  • 15. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.
    Spitz R, Hero B, Simon T, Berthold F.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3368-73. PubMed ID: 16740759
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.